Skip to Content

'
Ashraful Hoque, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor (Tenured), Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor (Tenured), Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Ashraful Hoque is an Associate Professor in the Departments of Clinical Cancer Prevention and Epidemiology, Division of Cancer Prevention and Population Sciences at the University of Texas M. D. Anderson Cancer Center. Dr. Hoque’s major research focus is molecular epidemiologic and translational biomarker studies in the area of hormonally-regulated cancer, particularly of the prostate and breast. The primary research focus is to define the molecular risks for prostate and breast cancer to discover effective ways of preventing these diseases in high-risk men and women. Dr. Hoque has major team-science collaborations in prostate and breast cancer prevention research involving investigators of both inside and outside of M. D. Anderson Cancer Center (MDACC). Currently, Dr. Hoque is leading an investigation that utilizes the biospecimens and clinical and epidemiologic data collected in the Prostate Cancer Prevention trial (PCPT). The objective is to examine genetic variations in steroid metabolic genes, oxidative stress-related genes, and DNA repair genes in association with the risk of prostate cancer and the pharmacogenetics of finasteride. Dr. Hoque is also investigating estrogen metabolism and action in prostate cancer etiology in the PCPT. He is also the founding member of the Molecular Epidemiology Committee of Southwest Oncology Group (SWOG) and a key investigator of the SELECT. He is continuing the translational biomarker studies of ductal carcinoma in situ (DCIS) of the breast. Also, he is actively involved with MDCC’s NCI-supported early drug development consortium for chemoprevention trials and overseeing the institutional SWOG programs for therapy trials.

Research Interests

  • Prostate Cancer
  • DCIS
  • Chemoprevention
  • Molecular Epidemiology
  • Translational Studies
  • SWOG

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler St.
PO Box 301439
Unit Number: 1360
Houston, TX 77230-1439
Room Number: CPB6.3494
Phone: 713/745-2544
Fax: 713/563-5747
Email: ahoque@mdanderson.org

Education & Training

Degree-Granting Education

1997 The University of Texas School of Public Health, Houston, TX, PHD, Epidemiology
1990 University of Western Australia, Perth, Western Australia, Australia, MS, Epidemiology
1981 Rajshahi Medical College, Rajshahi, Bangladesh, MBBS, Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2002-9/2008
Assistant Professor, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2001-8/2008
Instructor, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1998-2001
Research Associate, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1994-1998
Research Associate, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1994
Postdoctoral Fellow, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1993-1994
Graduate Research Assistant, The University of Texas School of Public Health, Houston, TX, 1991-1993

Administrative Appointments/Responsibilities

Served as international student representative for the search committee to recruit the Director of International Affairs, The University of Texas Health Science Center, Houston, TX, 1994
Served as member of search committee for recruitment of three faculty members in the department of Epidemiology, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 1994
Deputy Medical Director, Global 2000 Inc, Dhaka, Bangladesh, 1987-1988
Medical Officer, CARE-INTERNATIONAL, Dhaka, Bangladesh, 1983-1987
Medical Officer, Matlab Upazila Health Complex, Government of Bangladesh, Matlab Upazila, 1982-1983
Assistant Surgeon, Rajshahi Medical College Hospital, Rajshahi, Bangladesh, 1981-1982

Institutional Committee Activities

Member, Psychosocial, Behavioral, and Health Services Research Committee (PBHSRC), 2010-present
Member, Institutional Research Grants Program (IRG) Review Committee, 2010-present
Member, Clinical Cancer Prevention Retreat Organizing Committee, 2010
Member, Day of Prevention Science Organizing Committee, 2009
Member, Institute for Personalized Cancer Therapy (IPCT) Scientific Review Committee, 2008-present
Member, Executive Committee N01, Phase 1 and 2 Clinical Trials of Cancer Chemopreventive Agents, 2007-present
Member, Cancer Prevention Center Scientific Committee, The University of Texas M. D. Anderson Cancer Center, 2006-present
Member, R25 Education Program Evaluation Committee, 2006-present
Senator, Faculty Senate, The University of Texas M. D. Anderson Cancer Center, 2004-2006
Member, Executive Committee U10, Southwest Oncology Clinical Trial Program, The University of Texas M. D. Anderson Cancer Center, 2003-present
Member, Psychosocial, Behavioral & Health Services Research Committee, The University of Texas M. D. Anderson Cancer Center, 1999-2003

Honors and Awards

2010-present Editorai Board Member, ISRN Oncology
2008-present DoD Study Section Member
2007-present Editorial Board Member, Cancer Epidemiology Biomarkers & Prevention
2007-present NIH Study Section Member (Adhoc)
2004-2005 VA Study Section Member (Adhoc)
2000 Travel award to attend 91st Annual Meeting of the American Association for Cancer Research (AACR), San Francisco, California, Division of Cancer Prevention, The University of Texas M. D. Anderson Cancer Center
1996 Travel award to attend 30th Annual Meeting of Society for Epidemiologic Research (SER), Edmonton, Canada, Michigan Department of Public Health
1996 Travel award to attend VIth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer at Princeton, New Jersey, Immunomedics, Inc
1994 Partial financial support to attend New Investigators Workshop, 19th Annual Meeting of the American Society of Preventive Oncology (ASPO)

Selected Publications

Peer-Reviewed Original Research Articles

1. Hu Y, Correa AM, Hoque A, Guan B, Ye F, Huang J, Swisher SG, Wu TT, Ajani JA, Xu XC. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer 128(1):132-43, 1/2011. e-Pub 3/2010. PMCID: PMC2937084.
2. Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW, Reichardt JK, Hoque A, Tangen CM, Kristal AR, Thompson IM, Figg WD. Androgen Receptor CAG Repeat Length and Association With Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. J Urol 184(6):2297-302, 12/2010. e-Pub 10/2010. PMID: 20952028.
3. Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Lucia MS, Platz EA, Figg WD, Hoque A, Hsing A, Neuhouser ML, Parnes HL, Reichardt JK, Santella RM, Till C, Lippman SM. Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res (Phila) 3(12):1523-33, 12/2010. PMCID: PMC3058741.
4. Platz EA, Sutcliffe S, De Marzo AM, Drake CG, Rifai N, Hsing AW, Hoque A, Neuhouser ML, Goodman PJ, Kristal AR. Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies. Cancer Causes Control 21(6):847-51, 6/2010. e-Pub 2/2010. PMCID: PMCPMC3010861.
5. Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen C, Kristal A, Lucia S, Wang Q, Kappil M, Thompson I, Hsing AW, Parnes H, Santella RM. Serum Oxidized Protein and Prostate Cancer Risk within the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila Pa) 3(4):478-83, 4/2010. e-Pub 3/2010. PMCID: PMC2853720.
6. Neuhouser ML, Till C, Kristal A, Goodman P, Hoque A, Platz EA, Hsing AW, Albanes D, Parnes HL, Pollak M. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila Pa) 3(3):279-89, 3/2010. e-Pub 2/2010. PMCID: PMCPMC2564287.
7. Sutcliffe S, Viscidi RP, Till C, Goodman PJ,Hoque A, Hsing AW, Thompson IM, Zenilman JM, De Marzo AM, Platz EA. Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 19(2):614-8, 2/2010. PMCID: PMC2820385.
8. Musumeci L, Arthur JW, Cheung FS, Hoque A, Lippman S, Reichardt JK. Single nucleotide differences (SNDs) in the dbSNP database may lead to errors in genotyping and haplotyping studies. Hum Mutat 31(1):67-73, 1/2010. PMCID: PMC2797835.
9. Song S, Guan B, Men T, Hoque A, Lotan R, Xu XC. Antitumor effect of retinoic acid receptor-beta2 associated with suppression of cyclooxygenase-2. Cancer Prev Res (Phila Pa) 2(3). e-Pub 3/2009. PMCID: PMCPMC3415716.
10. Guan B, Chen Y, Hoque A, Xu X-C. Characterization of Retinoid Receptor-Induced Gene-1 Gene and Its Relationship to SH3 Domain GRB2-Like Endophilin B2 Gene. J Cancer Mol 5:15-19, 2009.
11. Hoque A, Goodman P, Ambrosone CB, Figg WD, Price DK, Kopp W, Wu X, Conroy J, Lehman TA, Santella RM. Extraction of DNA from Serum for High-throughput Genotyping: Findings from Pilot Studies within the Prostate Cancer Prevention Trial. Urology 71(5):967-70, 2008. e-Pub 2/2008. PMCID: PMC2387066.
12. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 17(1):88-94, 2008. PMID: 18199714.
13. Hoque A, Parnes HL, Stefank ME, Haymach JV, Brown PH, and Lippman SM. Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research. Cancer Res 67:8989-8993, 2007.
14. Huang J, Liang ZD, Wu TT, Hoque A, Chen, H., Jiang Y, Zhang H, and Xu X-C. Tumor-suppressive effect of retinoid receptor-induced gene-1 (RRIG1) in esophageal cancer. Cancer Res 67:1589-93, 2007.
15. De Marzo AM, Platz EA , Epstein JI , Ali T , Billis A, Chan TY, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X , Fine SW , Iczkowski KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Pikarsky E, Pizov G, Rubin MA, Samaratunga H, Sebo T, Sesterhenn IA, Shah RB, Signoretti S, Simko J ,Thomas G, Troncoso P, Tsuzuki T, van Leenders G JLH, Yang XJ, Zhou M, Figg WD, Hoque A, Lucia MS. A Working Group Classification of Focal Prostate Atrophy Lesions. Am J Surg Pathol 30:1281-91, 2006.
16. Kuptsova N , Kopecky KJ, Godwin J, Anderson J, Hoque A,, Willman CL, and Ambrosone CB. DNA repair gene polymorphisms and therapeutic outcome of AML patients from SWOG clinical trials. Blood 109:3936-44, 2006.
17. Weiss JR, Kopecky KJ, Godwin J, Anderson J, Willman CL, Moysich KB, Slovak ML, Hoque A, Ambrosone CB. Glutathione S-transferase (GSTM1, GSTT1 and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia: pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials. Leukemia 20:2169-71, 2006.
18. Kristal AR, King IB, Albanes D, Pollak MN, Stanzyk FZ, Santella RM, Hoque A,. Centralized blood processing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones and lymphocyte viability. Cancer Epidemiol Biomarkers Prev 14:727-30, 2005. PMID: 15767358.
19. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM, Jr, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, Schwartz GG, Ford LG, Coltman CA, Jr. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 97:94-102, 2005. PMID: 15657339.
20. Hoque A, Lippman SM, Xu Y, Swisher S, Wu T-T, Zhang H, Cao L, Ajani JA, Xu X-C. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 26:785-91, 2005.
21. Xu X-C, Lee JJ, Wu T-T, Hoque A, Ajani JA, Lippman SM. Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma. Cancer Epidemiol Biomark Prev 14:826-829, 2005.
22. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7:280-93, 2005. PMID: 15799828.
23. Liu J, Baykal A, Fung KM, Thompson-Lanza JA, Hoque A, Lippman SM, Sahin A. Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ. Int J Oncol 24:879-84, 2004. PMID: 15010825.
24. Hoque A, Carter J, Xia W, Hung MC, Sahin AA, Sen S, Lippman SM. Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. Cancer Epidemiol Biomarkers Prev 12:1518-22, 2003. PMID: 14693746.
25. Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman SM, Bast RC, Jr, Yu Y. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res 9:3660-6, 2003. PMID: 14506155.
26. Hoque A, Sneige N, Sahin AA, Menter DG, Bacus JW, Hortobagyi GN, Lippman SM. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 11:587-90, 2002. PMID: 12050101.
27. Singletary SE, Atkinson EN,Hoque A, Sneige N, Sahin AA, Fritsche HA, Jr, Lotan R, Lu T, Hittelman WN, Bevers TB, Stelling CB, Lippman SM. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 8:2835-42, 2002. PMID: 12231524.
28. Menter DG, Hoque A, Motiwala N, Sahin AA, Sneige N, Lieberman R, Lippman SM. Computerized image analysis of Ki-67 in ductal breast carcinoma in situ. Anal Quant Cytol Histol 23:218-28, 2001. PMID: 11444192.
29. Hoque A, Albanes D, Lippman SM, Spitz MR, Taylor PR, Klein EA, Thompson IM, Goodman P, Stanford JL, Crowley JJ, Coltman CA, Santella RM. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control 12:627-33, 2001. PMID: 11552710.
30. Hoque A, Menter DG, Sahin AA, Sneige N, Lippman SM. No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer. Cancer Epidemiol Biomarkers Prev 10:153-4, 2001. PMID: 11219775.
31. Patt YZ, Hassan MM, Lozano RD, Waugh KA, Hoque A, Frome AI, Lahoti S, Ellis L, Vauthey JN, Curley SA, Schnirer II, Raijman I. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 7:3375-80, 2001. PMID: 11705850.
32. Hoque A, Lippman SM, Boiko IV, Atkinson EN, Sneige N, Sahin A, Weber DM, Risin S, Lagios MD, Schwarting R, Colburn WJ, Dhingra K, Follen M, Kelloff GJ, Boone CW, Hittelman WN. Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 10:249-59, 2001. PMID: 11303595.
33. Hoque A, Patt YZ, Yoffe B, Groopman JD, Greenblatt MS, Zhang YJ, Santella RM. Does aflatoxin B1 play a role in the etiology of hepatocellular carcinoma in the United States? Nutr Cancer 35:27-33, 1999. PMID: 10624703.
34. Patt YZ, Hoque A, Roh M, Ellis L, Lozano R, Carrasco CH, Charnsangavej C, Cleary K. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. Am J Clin Oncol 22:209-13, 1999. PMID: 10199464.
35. Sneige N, Lagios MD, Schwarting R, Colburn W, Atkinson E, Weber D, Sahin A, Kemp B, Hoque A, Risin S, Sabichi A, Boone C, Dhingra K, Kelloff G, Lippman S. Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ. Hum Pathol 30:257-62, 1999. PMID: 10088542.
36. Hoque A, Sigurdson AJ, Burau KD, Humphrey HE, Hess KR, Sweeney AM. Cancer among a Michigan cohort exposed to polybrominated biphenyls in 1973. Epidemiology 9:373-8, 1998. PMID: 9647899.
37. Patt YZ, Hoque A, Lozano R, Pozdur R, Chase J, Carrasco H, Chuang V, Delpassand ES, Ellis L, Curley S, Roh M, Jones DV, Jr. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin. J Clin Oncol 15:1432-8, 1997. PMID: 9193336.
38. Jones, DV, Chase J, Roh M, Hohn DC, Curley S, Smith R, Hoque A, Patt YZ. A phase I evaluation of chronotropic delivery of floxuridine by hepatic arterial infusion in patients with metastatic colorectal cancer. Oncol Rpts 3:391-396, 1996.
39. Hoque A, Selwyn BJ. Birth practice patterns in urban slums of Dhaka, Bangladesh . Women Health 24:41-58, 1996.
40. Jones DV, Jr, Lozano R, Hoque A, Markowitz A, Patt YZ. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 14:2306-10, 1996. PMID: 8708721.
41. Patt YZ, Jones DV, Jr, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 14:2311-5, 1996. PMID: 8708722.
42. Spitz MR, Hoque A, Trizna Z, Schantz SP, Amos CI, King TM, Bondy ML, Hong WK, Hsu TC. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst 86:1681-4, 1994. PMID: 7966395.

Abstracts

1. Hoque A, Chen H, Xu XC. RRIG1 Suppress Growth and Invasion of Prostate Cancer Cell Lines Through Inactivation of SRC and RhoA. Proc Amer Assoc Cancer Res, 4/2010.
2. Hoque A, Chen H, Guan B and Xu X-C. Tumor-Suppressive Effect of RRIG1 in Prostate Cancer. Proc Amer Assoc Cancer Res, 2009.
3. Xu X, Hoque A, Song S, Men T, Chen H, Lotan R, and Lippman S. Antitumor effect of retinoic acid receptor-2β requires suppression of cyclooxygenase-2 expression. Proc Amer Assoc Cancer Res, 2007.
4. Hoque A, Chen H, Xu XC. Effectiveness of statin in inducing apoptosis and cell growth arrest via inactivating RhoA in prostate cancer cell lines. Proc Amer Assoc Cancer Res, 2006.
5. Hoque A, Strom SS. Obesity and androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Proc Amer Assoc Cancer Res 47:285, 2006.
6. Menter DG, Hsi L, Reddy SA, Hoque A, Llansa ND, Mendoza G, Li Y, Xi X, Abbruzzesse JL, Bresalier RS, Lippman SM, Krishnan K. Targeting HMG Co-A Reductase for Chemoprevention: Differential Effects of Pravastatin and Simvastatin on the Growth of Tumor Cells from Different Organ Sites. Keystone Symposium - Molecular Targets for Cancer Prevention, 2006.
7. Hoque A, Xu Y, Swisher S, Wu T-T, Zhang H, Cao L, Ajani JA, Lippman SM, Xu X-C. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Proc Amer Assoc Cancer Res 46:374, 2005.
8. De Marzo, AM, Platz EA, Epstein J I, Baydar D, Billis A, Chan T, Datta M, Farre X, Fine S, Iczkowski K, Ittmann M, Knudsen B, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Rubin M, Sebo T, Sesterhenn I, Shah R, Signoretti S, Simpko S, Troncoso P, Tsuzuki T, van Leenders A, Yang X, Zhou M, Figg W, Hoque A, Lucia MS. Interobserver reproducibility of a proposed classification of focal prostate atrophy lesions. United States and Canadian Acad Pathol Annual Mtg 30:1281-1291, 2004.
9. Banerjee, D, Choe JM, Ward D, Hoque A, Basen-Engquist K, Song J, Ramsey D, Lippman SM, Cook ED. Participant’s perception of recruitment and retention in the Selenium and Vitamin E Cancer Prevention Trial. Frontiers of Cancer Prev Res Amer Assoc Cancer Res, Cance Epi demiol Biomarkers Prev 13:1889S, 2004.
10. Hoque A, Xu X-C, Xu Y, Menter DG, Lippman SM. Patterns of 5-LOX expression in prostate cancer and effect of 5-LOX inhibitors on prostate cancer cell proliferation and apoptosis. Proc Amer Assoc Cancer Res 45:1092, 2004.
11. Hoque A, Xu XC, Sahin A, Lippman SM. Expression of 15-LOX-2 in ductal carcinoma in situ, invasive carcinoma and adjacent normal mammary ducts of the breast. Proc Amer Assoc Cancer Res, 2003.
12. Hoque A, Sahin A, Xia W, Sneige N, Lippman SM, Aldaz CM. Loss of heterozygosity and HER-2/neu gene amplification in ductal carcinoma in situ of the breast. Frontiers of Cancer Prev Res, Amer Assoc Cancer Res. Cancer Epidemiol Biomarkers Prev 11:B311, 2002.
13. Hoque A, Sahin A, Xia W, Sneige N, Lippman SM, Sen S. STK15/BTAK/aurora-A expression: a molecular marker of transition of in situ to invasive ductal carcinoma of the breast. Proc Amer Assoc Cancer Res 43:46(232), 2002.
14. Hoque A, Lippman SM, Boiko I, Atkinson N, Sneige N, Sahin A, Weber D, Risin S, Lagios M, Schwarting R, Colburn WJ, Dhingra K, Follen M, Kelloff GJ, Boone CW, Hittelman WN. Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast. Proc Amer Assoc Cancer Res 42:(1684), 2001.
15. Hoque A, Sahin A, Xia W, Zhou H, Sneige N, Hung M-C, Lippman SM, Sen S. STK15/BTAK//aurora-A expression in ductal carcinoma in situ of the breast. Breast Cancer Res Treatment 69:250(256), 2001.
16. Hoque A, Sneige N, Sahin A, Atkinson N, Weber D, Bacus JW, Lippman SM. Assessment of HER-2/NEU and quantitative nuclear morphometry in ductal carcinoma in situ (DCIS) of the breast. Proc Amer Assoc Cancer Res 41:223(1420), 2000.
17. Hoque A, Lippman SM, Sahin A, Atkinson N, Bacus JW, Sneige N. HER-2/NEU and nuclear morphometry in grading ductal carcinoma in situ (DCIS) of the breast. Breast Cancer Res Treatment 57:71(259), 1999.
18. Boiko, IV, Hoque A, Sneige N, Atkinson N, Sahin A, Sabichi AL, Weber D, Lagios M, Schwarting R, Colburn W, Dhingra K, Kelloff G, Silverstein M, Boone C, Lippman SM, Hittelman WN. Image analysis as predictive factor for recurrence of ductal carcinoma in situ. Proc Amer Assoc Cancer Res 40:431(2847), 1999.
19. Patt, YZ, Hassan MM, Lozano RD, Hoque A, Raijman I, Waugh KA. Phase II trial of cisplatin (p), intron ATM (I), adriamycinTM (A), and 5-fluorouracil (F) (PIAF) for biliary tree cancer (BTC). . Proc Amer Soc Clin Oncol 18:297a(#1139), 1999.
20. Hoque A, Lippman SM, Atkinson N, Boiko I, Sneige N, Sahin A, Sabichi AL, Weber D, Lagios M, Schwarting R, Colburn W, Dhingra K, Kelloff G, Silverstein M, Boone C, Hittelman WN. Predicting recurrent ductal carcinoma in situ (DCIS) of the breast: nuclear image analysis feature. Proc Amer Assoc Cancer Res 40:431(2846), 1999.
21. Hoque A, Atkinson N, Boiko I, Sneige N, Sahin A, Sabichi AL, Weber D, Lagios M, Schwarting R, Colburn W, Dhingra K, Kelloff G, Silverstein M, Boone C, Lippman SM, Hittelman WN. Recurrence in ductal carcinoma in situ (DCIS) of the breast and morphologic predictive image analysis features (PIAFs): a multi-center case control study. Breast Cancer Res Treatment 50:251(161), 1998.
22. Patt YZ, Hoque A, Lozano R, Curley S, Ellis L, Cleary K, Waugh K, Charnsangavej C. Systemic therapy with platinol, interferon alpha 2b, doxorubicin, and 5-fluorouracil (5-FU) (PIAF) for treatment of non-resectable hepatocellular carcinoma (HCC). Proc Amer Soc Clin Oncol 17:301a(1159), 1998.
23. Hoque A, Sigurdson A, Burau K, Humphrey H, Sweeney A. Cancer among a Michigan cohort exposed to polybrominated biphenyls in 1973. Amer J Epi 145:S4, 1997.
24. Patt YZ, Yoffe B, Hoque A, Groopman JD, Greenblatt MS, Harris CC, Zhang YJ, Santella RM. Does aflatoxin (AFB1) play a role in the etiology of hepatocellular carcinoma (HCC) in the United States (U.S.)?. Proc Amer Soc Clin Oncol 16:539a, 1997.
25. Sigurdson A, Hoque A, Strom S. Does recruitment with reply cards result in spurious differences among responders and non-responders?. Amer J Epidem 145:S44(174), 1997.
26. Patt YZ, Hoque A, Podoloff DA, Pinsky CM, Goldenberg DM. CEA-SCANTM a 99m Tc-labeled Fab’ fragment of MoAb anti-CEA Immu-4 for radioimmuno-detection (RAID) of occult metastatic colorectal cancer (CRC) in patients (pts.) with rising serum CEA: a multi-institutional study. Proc Amer Soc Clin Oncol 475, 1996.
27. Hoque, A, Chase J, Lozano R, Markowitz A, Jones DV Jr, Carrassco H, Roh MS, Curley SA, Patt YZ. Educating patients on hepatic arterial infusion (HAI) as an option for treatment of hepatocellular carcinoma (HCC) and colorectal cancer metastatic to the liver. J Cancer Educ 10:32, 1995.
28. Patt YZ, Hoque A, Jones D, Markowitz A. Phase II trial of cisplatinum, 5-FU, and leucovorin (PFL) for primary duodenal carcinoma (PDC). Proc Amer Soc Clin Oncol 14:562, 1995.

Grant & Contract Support

Title: Pilot Biomarker Study of Trace Metals and Prostate Cancer Risk
Funding Source: Duncan Family Institute
Role: Principal Investigator
Duration: 10/1/2010 - 9/30/2013
 
Title: Renewal of U10 Full Member Application Affiliated with SWOG, Step down from Co-PI position
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Roy Herbst
Duration: 1/1/2010 - 12/31/2016
 
Title: Circadian Genes and Prostate Cancer Risk, Step down from Co-PI position
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Co-Investigator
Principal Investigator: Ann Hsing
Duration: 9/1/2009 - 9/30/2011
 
Title: CYCORE: CYberinfrastructure for COmparative effectiveness Research, Step down from Co-PI position
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 9/1/2009 - 8/31/2011
 
Title: Estrogen Metabolism and Action in Prostate Cancer Etiology in the PCPT, Step down from Co-PI position
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2006 - 2/28/2010
 
Title: Biology of the Prostate Cancer Prevention Trial (PCPT), Step down from Co-PI position
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: Dr. Ian Thompson
Duration: 5/1/2005 - 4/1/2012
 
Title: U10 Full Member Application Affiliated with SWOG, Step down from Co-PI position
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Dr. Scott M. Lippman
Duration: 7/26/2004 - 12/31/2009
 
Title: Phase I and Phase II Clinical Trials of Cancer Chemopreventive Agents, Step down from Co-PI position
Funding Source: National Cancer Institute-DHHS-NIH
Role: Co-Principal Investigator
Principal Investigator: Powel Brown
Duration: 9/30/2003 - 9/29/2013
 
Title: Phase 1 and 2 Clinical Trials of Cancer Chemopreventive Agents, Step down from Co-PI position
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Dr. Powel Brown
Duration: 9/30/2003 - 9/29/2012

Last updated: 7/24/2014